Registries

Pharmacoepidemiology, Fifth Edition

Volumn , Issue , 2012, Pages 331-346

  Dreyer, Nancy A ^a   Velentgas, Priscilla ^a  

^a Outcome Sciences Inc   (United States)

Author keywords

Comparative effectiveness; Effectiveness; Pharmacoepidemiology; Pharmacovigilance; Pregnancy registry; Product safety; Registry

Indexed keywords

EID: 84888765832     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781119959946.ch21     Document Type: Chapter

References (76)

1. Graunt J. Natural and Political Observations Mentioned in a Following Index and Made Upon the Bills of Mortality. New York: Arno Press , 1975. [Reprint of the 1662 edition.]
2. Vandenbroucke J. Observational research, randomised trials, and two views of medical science . PLOS Med 2008; 5: 339-43.
3. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies and the hierarchy of research designs . N Engl J Med 2000; 342: 1887-92.
4. Rawlins, MD, De Testimonio. On the evidence for decisions about the use of therapeutic interventions . Clin Med 2008; 8: 579-88.
5. Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research . N Engl J Med 2007; 357: 2219-21.
6. Gliklich RE, Dreyer NA, eds. Registries for Evaluating Patient Outcomes: A User ' s Guide, 2nd edn . (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.) AHRQ Publication No. 10 -EHC049. Rockville, MD: Agency for Healthcare Research and Quality , 2010.
7. Mahon BE, Shea KM, Dougherty NN, Loughlin AM. Implications for registry -based vaccine effectiveness studies from an evaluation of an immunization registry: A cross -sectional study . BMC Public Health 2008; 8: 160.
8. Samuels RC, Appel L, Reddy SI, Tilson RS. Improving accuracy in a computerized immunization registry . Ambul Pediatr 2002; 2: 187-92.
9. Wood D, Saarlas KN, Inkelas M, Matyas BT . Immunization registries in the United States: implications for the practice of public health in a changing health care system . Annu Rev Public Health 1999; 20: 231-55.
10. Zaroff JG, diTommaso DG, Barron HV . A risk model derived from the National Registry of Myocardial Infarction 2 database for predicting mortality after coronary artery bypass grafting during acute myocardial infarction . Am J Cardiol 2002; 90: 1-4.
11. Cystic Fibrosis Foundation . Patient Registry Report. www.cff.org/LivingWithCF/QualityImprovement/ PatientRegistryReport (accessed May, 2010).
12. Adisasmito W, Chan PKS, Lee N, Oner AF , Gasimov V, Aghayev F, et al. Effectiveness of antiviral treatment in human influenza H5N1 infections: analysis from a global patient registry . J Infect Dis 2010; 202: 1154-60.
13. Oner AF , Bamgboye E, Gasimov V, Zaman M, Chan PKS, Lee N, et al. Avian Influenza Infections in Children: Symptoms and Treatment. European Society for Paediatric Infectious Diseases, Nice, France, May, 2010.
14. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women . N Engl J Med 1971; 284: 878-81.
15. Herbst AL, Kurman RJ, Scully RE. Clear -cell adenocarcinomas of the genital tract in young females. Registry report . N Engl J Med 1972; 287: 1259-64.
16. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher Registry: demographics and disease characteristics of 1698 patients with Gaucher disease . Arch Intern Med 2000; 160: 2835-43.
17. Friedberg JW , Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: First report of the national lymphocare study . J Clin Oncol 2009; 27: 1202-8.
18. Massop D, Dave R, Metzger C, Bachinsky W, Solis M, Shah R, et al. Stenting and angioplasty with protecting in patients at high -risk for endarterectomy: SAPPHIRE worldwide registry first 2,001 patients . Catheter Cardiovasc Interv 2009; 73: 129-36.
19. Xian Y, Pan W, Peterson ED, Heidenreich PA , Cannon CP , Hernandez AF , et al. Are quality improvements associated with the Get With the Guidelines -Coronary Artery Disease (GWTG -CAD) program sustained over time? A longitudinal comparison of GWTG -CAD hospitals versus non -GWTG-CAD hospitals . Am Heart J 2010; 159: 207-14.
20. Illinois Department of Public Health . Illinois Comprehensive Automated Immunization Registry Exchange (I - CARE) Fact Sheet. http://www.idph. state.il.us/health/vaccine/icarefs.html (accessed Aug., 2010).
21. ISPE. Guidelines for good pharmacoepidemiology practices (GPP) . Pharmacoepidemiol Drug Saf 2008; 17: 200-8.
22. Rothman KH, Greenland S, Lash TL. Modern Epidemiology, 3rd edn . New York: Lippincott Williams and Wilkins , 2008.
23. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzche PC, Vandenbroucke JP . The strengthening the report ing of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies . Ann Intern Med 2007; 147: 573-7.
24. Dreyer NA, Schneeweiss S, McNeil B, Berger ML, Walker A, et al, on behalf of the GRACE Initiative. GRACE principles: recognizing high -quality observational studies of comparative effectiveness . Am J Manag Care 2010; 16: 467-71.
25. Wennberg DE, Lucas FL, Birkmeyer JD, Bredenberg CE, Fisher ES. Variation in carotid endarterectomy mortality in the medicare population: trial hospitals, volume, and patient characteristics . JAMA 1998; 279: 1278-81.
26. Kaufman PA , Dreyer NA, Mayer M, Sloan JA, Chung CY , Sing A, et al. Capturing breast cancer patients experience beyond disease progression: implementation of a patient - reported outcome (PRO) substudy in the VIRGO metastatic breast cancer observational cohort study. American Society of Clinical Oncology, Chicago, June, 2010.
27. National Institute of Arthritis and Musculoskeletal and Skin Diseases, US Department of Health and Human Services . Patient Research Registries. http:// www.niams.nih.gov/Funding/Funded_Research/ registries.asp (accessed May, 2010).
28. National Cancer Institute . Surveillance, Epidemiology, and End Results. Overview of the SEER Program. http:// seer.cancer.gov/about/ (accessed May, 2010).
29. Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development . Oral contraceptive use and risk of breast cancer . N Engl J Med 1986; 315: 405-11.
30. Anon. Oral contraceptive use and the risk of ovarian cancer . JAMA 1983; 249: 1596-9.
31. Anon. Oral contraceptive use and the risk of endometrial cancer . JAMA 1983; 249: 1600-4.
32. Shavers VL, Harlan LC, Jackson M, Robinson J. Racial/ethnic patterns of care for pancreatic cancer . J Palliat Med 2009; 12: 623-30.
33. Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States . Gynecol Oncol 2008; 108: 577-83.
34. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975 -1999. J Natl Cancer Inst Monogr 2006; 36: 7-15.
35. National Cancer Institute . Surveillance, Epidemiology, and End Results Program. SEER - Medicare Linked Database. http://seer.cancer.gov/about/seermedicare. html (accessed May, 2010).
36. Cheung WY , Neville BA, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and their impact on outcomes for Stage II and III rectal cancer . Dis Colon Rectum 2009; 52: 1054-63; discussion 1064.
37. Hershman DL, Buono D, McBride RB, Tsai WY , Neugut AI. Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women . Cancer 2009; 115: 3848-57.
38. Breslin TM, Morris AM, Gu N, Wong SL, Finlayson EV , Banerjee M, et al. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer . J Clin Oncol 2009; 27: 3945-50.
39. Rouhani P, Arheart KL, Kirsner RS. Differences in melanoma outcomes among Hispanic Medicare enrollees. J Am Acad Dermatol 2010; 62: 768-76.
40. US Hereditary Angioedema Association . US HAE Scientific Registry: Patient Driven Research for a Cure. http://www.haea.org/get -involved/us-haea-scientific -registry/ (accessed June 2011).
41. Dreyer NA, Garner S. Registries for robust evidence . JAMA 2009; 302: 790-1.
42. Douglas PS, Brennan JM, Anstrom KJ, Sedrakyan A, Eisenstein EL, et al. Clinical effectiveness of coronary stents in the elderly: results from 262,700 Medicare patients in ACC -NCDR. J Am Coll Cardiol 2009; 53: 1629-41.
43. Center for Biologics Evaluation and Research (CBER) , Food and Drug Administration, United States Department of Health and Human Services. Guidance for Industry: Gene Therapy Clinical Trials - Observing Subjects for Delayed Adverse Events. http://www.fda.gov/BiologicsBlood Vaccines/GuidanceComplianceRegulatoryIn formation/ Guidances/CellularandGeneTherapy/ucm072957.htm (accessed May, 2010).
44. Committee for Medicinal Products for Human Use (CHMP). Guideline on Safety and Efficacy Follow - Up - Risk Management of Advanced Therapy Medicinal Products, Doc. Ref. EMEA/149995/2008 . European Medicines Agency, 2008.
45. Hobbs MN. Registries rising: FDA looking at TNF inhibitors; AHRQ updates standards . Pink Sheet 2009; 71: 8-9.
46. Sedrakyan A, Marinac-Dabic D, Normand SL, Mushlin A, Gross T. Framework for evidence evaluation and methodological issues in implantable device studies. Med Care 2010; 48 (6 Suppl): S121-8.
47. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Establishing Pregnancy Exposure Registries. Food and Drug Administration, United States Department of Health and Human Services. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071639.pdf(accessed April, 2010).
48. Committee for Medicinal Products for Human Use (CHMP). Guideline on the Exposure to Medicinal Products During Pregnancy: Need for Post - Authorisation Data, EMEA/CHMP/313666/2005. European Medicines Agency, Adopted November 2005. http://www. ema.europa.eu/pdfs/human/phvwp/31366605en.pdf(accessed April, 2010).
49. Cnattingius S, Eriksson A, Gunnarskog J, Källén B. A quality study of a medical birth registry . Scand J Soc Med 1990; 18: 143-8.
50. Almgren M, Källén B, Lavebratt C. Population-based study of antiepileptic drug exposure in utero - influence on head circumference in newborns . Seizure 2009; 18: 672-5.
51. Wikner BN, Sparre LS, Stiller CO, Källén B, Asker C. Maternal use of thyroid hormones in pregnancy and neonatal outcome . Acta Obstet Gynecol Scand 2008; 87: 617-27.
52. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome . J Clin Psychopharmacol 2008; 28: 279-88.
53. Källén B, Nilsson E, Otterblad Olausson P. Maternal use of loperamide in early pregnancy and delivery outcome. Acta Paediatr 2008; 97: 541-5.
54. Källén B, Otterblad Olausson P. Use of anti -asthmatic drugs during pregnancy. 1. Maternal characteristics, pregnancy and delivery complications . Eur J Clin Pharmacol 2007; 63: 363-73.
55. Nygren KG, Finnström O, Källén B, Olausson PO. Population-based Swedish studies of outcomes after in vitro fertilisation . Acta Obstet Gynecol Scand 2007; 86: 774-82.
56. Linet MS, Gridley G, Cnattingius S, Nicholson HS, Martinsson U, Glimelius B, et al. Maternal and perinatal risk factors for childhood brain tumors (Sweden). Cancer Causes Control 1996; 7: 437-48.
57. Covington DL, Tilson H, Elder J, Doi P. Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the Antiretroviral Pregnancy Registry . Pharmacoepidemiol Drug Saf 2004; 13: 537-45.
58. Antiretroviral Pregnancy Registry Steering Committee . Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2009. Wilmington, NC: Registry Coordinating Center , 2009. http://www.APRegistry.com (accessed June 2011).
59. Watts DH, Covington DL, Beckerman K, Garcia P, Scheuerle A, Dominguez K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy . Am J Obstet Gynecol 2004; 191: 985-92.
60. Center for Drug Evaluation and Research (CDER) . Public Workshop on Developing a Consolidated Pediatric Rheumatology Observational Registry, May 12 - 13, 2009. http://www.fda.gov/downloads/Drugs/NewsEvents/ UCM171762.pdf(accessed May, 2010).
61. Food and Drug Administration, United States Department of Health and Human Services . Postmarket Requirements and Commitments. http://www.accessdata. fda.gov/scripts/cder/pmc/index.cfm (accessed May, 2010).
62. Curtis JP , Luebbart JJ, Wang Y, Rathmore SS, Chen J, Heidenreich PA , et al. Association of physician certification and outcomes among patients receiving an implantable cardioverter -defibrillator . JAMA 2009; 301: 1661-70.
63. LaBresh KA, Gliklich R, Liljestrand J, Peto R, Ellrodt AG. Using "get with the guidelines " to improve cardiovascular secondary prevention . Jt Comm J Qual Saf 2003; 29: 539-50.
64. Hillner BE, Siegel BA, Liu D, Shields AF , Gareen IF , Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET registry . J Clin Onc 2008; 26: 5316-19.
65. Krishnan JA, Mularski RA. Acting on comparative effectiveness research in COPD . JAMA 2010; 303: 2409-10.
66. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox PW , Gliklich RE. Why observational studies should be among the tools used in comparative effectiveness research. Health Affairs 2010; 29: 1818-25.
67. Food and Drug Administration, United States Department of Health and Human Services . FDA ' s Sentinel Initiative: Transforming How we Monitor the Safety of FDA - related Products. http://www.fda.gov/ Safety/FDAsSentinelInitiative/default.htm (accessed May, 2010).
68. Platt R,Wilson M, Chan KA, Benner JS, Marchibroda J, McClellan M. The new sentinel network - improving the evidence of medical -product safety . N Engl J Med 2009; 361: 645-7.
69. Institute of Medicine . 100 Initial Priority Topics for Comparative Effectiveness Research. http://www. iom.edu/~/media/Files/Report%20Files/2009/ ComparativeEffectivenessResearchPriorities/Stand% 20Alone%20List%20of%20100%20CER%20 Priorities%20-%20for%20web.ashx (accessed May, 2010).
70. Genzyme. Pompe Registry . https://www.lsdregistry. net/pomperegistry (accessed June, 2010).
71. European Medicines Agency . PROTECT . http:// www.imi -protect.eu (accessed May, 2010).
72. Merlo J, Chaix B, Yang M, Lynch J, Rastam L. A brief conceptual tutorial of multilevel analysis in social epidemiology: linking the statistical concept of clustering to the idea of contextual phenomenon . J Epidemiol Comm Health 2005; 59: 443-9.
73. Diez-Roux AV. Multilevel analysis in public health research. Annu Rev Public Health 2000; 21: 171-92.
74. Leyland AH, Goldstein H, eds. Multilevel Modeling of Health Statistics. Wiley , 2001.
75. Gort M, Otter R, Plukker JTM, Broekhuis M, Klazinga NS. Actionable indicators for short and long term outcomes in rectal cancer . Eur J Cancer 2010; 46: 1808-14.
76. Arnold M. Pfizer seeks ways to ease adverse events reporting digitally . Medical Marketing and Media, March 30, 2010 http://www.mmm -online.com/pfizer -seeksways-to-ease-adverse-events-reporting-digitally/ article/166947/ (accessed May, 2010).